These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The Health Care Burden of Hepatic Encephalopathy. Elsaid MI; John T; Li Y; Pentakota SR; Rustgi VK Clin Liver Dis; 2020 May; 24(2):263-275. PubMed ID: 32245532 [TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomics of hepatic encephalopathy. Neff G Pharmacotherapy; 2010 May; 30(5 Pt 2):28S-32S. PubMed ID: 20412038 [TBL] [Abstract][Full Text] [Related]
6. The burden of hepatic encephalopathy in Latin America. Dávalos Moscol M; Bustios Sanchez C Ann Hepatol; 2011 Jun; 10 Suppl 2():S31-5. PubMed ID: 22228878 [TBL] [Abstract][Full Text] [Related]
7. Update on management of patients with overt hepatic encephalopathy. Chacko KR; Sigal SH Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621 [TBL] [Abstract][Full Text] [Related]
12. Factors affecting compliance and persistence with treatment for hepatic encephalopathy. Neff G Pharmacotherapy; 2010 May; 30(5 Pt 2):22S-7S. PubMed ID: 20412037 [TBL] [Abstract][Full Text] [Related]
13. [Prognostic significance and economic burden of hepatic encephalopathy in liver cirrhosis in German hospitals based on G-DRG data]. Gundling F; Rathmayer M; Koller L; Wilke M; Kircheis G; Wedemeyer H; Labenz J; Albert J; Schepp W; Lerch MM; Z Gastroenterol; 2020 Apr; 58(4):323-331. PubMed ID: 31863425 [TBL] [Abstract][Full Text] [Related]
14. Covert hepatic encephalopathy: not as minimal as you might think. Kappus MR; Bajaj JS Clin Gastroenterol Hepatol; 2012 Nov; 10(11):1208-19. PubMed ID: 22728384 [TBL] [Abstract][Full Text] [Related]
15. [Evaluation of the burden of diabetes in Poland]. Kissimova-Skarbek K; Pach D; Płaczkiewicz E; Szurkowska M; Szybiński Z Pol Arch Med Wewn; 2001 Sep; 106(3):867-73. PubMed ID: 11928598 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy. Ahire K; Sonawale A J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305 [TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. Huang E; Esrailian E; Spiegel BM Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657 [TBL] [Abstract][Full Text] [Related]
18. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy. Flamm SL Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824 [TBL] [Abstract][Full Text] [Related]
19. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Neff GW; Kemmer N; Zacharias VC; Kaiser T; Duncan C; McHenry R; Jonas M; Novick D; Williamson C; Hess K; Thomas M; Buell J Transplant Proc; 2006 Dec; 38(10):3552-5. PubMed ID: 17175328 [TBL] [Abstract][Full Text] [Related]